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Abstract
Conclusions: CDH23 mutations and the 1555A>G mitochondrial mutation were identiﬁed among our series of electric acoustic
stimulation (EAS) patients, conﬁrming that these genes were important in hearing loss with involvement of high frequency.
Successful hearing preservation as well as good outcomes from EAS indicated that patients with this combination of mutations
are good candidates for EAS. Objectives: Screening for gene mutations that possibly cause hearing loss involving high frequency
was performed to identify the responsible genes in patients with EAS. In addition to a review of the genetic background of the
patients with residual hearing loss, the beneﬁt of EAS for patients with particular gene mutations was evaluated. Methods:
Eighteen patients (15 late-onset, 3 early-onset) with residual hearing who had received EAS were included in this study.
Genetic analysis was performed to identify GJB2, CDH23, SLC26A4, and the 1555 mitochondrial mutations. Results: Three
early-onset patients had CDH23 mutations. One late-onset patient had the 1555 A>G mitochondrial mutation.
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Introduction
Hearing loss in the majority of patients with residual
hearing at lower frequencies is more or less progres-
sive, although the speed of progression, i.e. rapid or
rather stable, may be dependent on the etiology. An
unresolved issue is the prediction of progressiveness
based on the etiology of individual hearing loss. We
have recently reported at least four genes that are
responsible for the candidates for electric acoustic
stimulation (EAS), and therefore there is not a single
etiology but rather a great genetic heterogeneity
involved in this particular type of hearing loss [1].
In this study, screening for mutations of four genes
(GJB2, CDH23, SLC26A4, and the 1555 mitochon-
drial mutations), which possibly cause high frequency
hearingloss,was performed to identify the responsible
genes for 18 patients with EAS.
Material and methods
Eighteen patients (8 males and 10 females, aged
1–68 years) were included in this study. Clinical
features of the subjects are summarized in Table I.
As regards onset of hearing loss, 15 patients were
late-onset (10–50 years old) and 3 patients were
early-onset (most probably congenital). Anamnestic
evaluation and/or serial audiogram indicated that all
of the patients had progressive sensorineural hearing
loss. No patients had any anomalies such as enlarged
vestibular aqueduct. All patients had some residual
hearinginthelowerfrequencies,andthereforereceived
EAS. The round window approach was applied for all
thepatients,andintraoperativeandpostoperativeintra-
venous administration of dexamethasone was used as
describedinapreviousreport[2].Forgeneticanalysis,
direct sequencing for GJB2, SLC26A4, CDH23, and
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Detailed methods are described elsewhere [3-6].
Results
All three early-onset patients had CDH23 mutations
(case nos 16, 17, and 18; Figures 1,2,3). One post-
lingual patient had the 1555 A>G mitochondrial
mutation (case no. 9; Figure 4). Hearing in the low
frequencies after cochlear implantation was well
preserved in all 18 cases including these 4 cases.
Case nos 16 and 17 (Figures 1 and 2)
The patients were 12-year-old twins, had the same
mutations in the CDH23 gene, and showed similar
audiograms and a slowly progressive nature con-
ﬁrmed by serial audiograms. Both had some residual
hearing in the lower frequencies and used hearing
aids, but due to the progression of their hearing
loss, they received cochlear implants (Nucleus
CI24M device, with complete insertion of a straight
array through cochleostomy) for the left ear at the age
of 5 (no. 16) and 6 (no. 17). In one of the twins
(no. 16) residual hearing was successfully preserved
(Figure 1D), but the other (no. 17) lost his air-
conduction thresholds after cochlear implantation
even though the bone-conduction threshold remained
stable (Figure 2D). Their audiological performance
was good with the cochlear implantation (electric
stimulation only). They wanted to have cochlear
implants on the other sides, considering their residual
hearing and the progressive nature of the hearing
loss, and we decided to use a longer atraumatic
electrode (MEDEL PULSAR CI100/FLEXsoft elec-
trode) to cover the low frequencies (Figure 1A, B, C;
Figure 2A, B, C). Hearing was well preserved
6 months postoperatively (Figures 1D and 2D).
Both had compound heterozygous mutations
(p.P240L/p.R301Q), and their parents were found
to be carriers for these mutations (Figure 2E). After
identiﬁcation of the CDH23 mutations, they were
referred for ophthalmologic examination including
electroretinography (ERG) and visual ﬁeld analysis.
Both had normal ERG response and no visual ﬁeld
deﬁcits, conﬁrming the nonsyndromic phenotype
(DFNB12). Furthermore, they did not have any ves-
tibular problems and showed normal responses in
caloric testing. Their hearing thresholds improved
to 30 dB and 35 dB (nos 16 and 17, respectively)
Table I. Clinical features of subjects in study.
Case no. Gender Age (EAS) Onset (age) Progressiveness Inheritance
mode
Responsible gene Implant Insertion
depth (mm)
1 F 59 Late (43) + Sporadic N/I PULSAR FLEXeas 24
2 F 71 Late (30) + AD N/I PULSAR FLEXeas 24
3 F 45 Late (25–30) + Sporadic N/I PULSAR FLEXeas 24
4 F 38 Late (34) + Sporadic N/I PULSAR FLEXeas 24
5 F 46 Late (30) + AD N/I PULSAR FLEXeas 24
6 M 29 Late (10) + AD N/I PULSAR FLEXeas 24
7 M 39 Late (20) + AD N/I PULSAR FLEXeas 24
8 F 35 Late (25) + Sporadic N/I PULSAR FLEXeas 24
9 M 52 Late (25) + Mitochondrial Mit. 1555A>G PULSAR FLEXeas 24
10 F 51 Late (30) + AD N/I PULSAR FLEXeas 24
11 M 39 Late (6) + Sporadic N/I PULSAR FLEXeas 24
12 F 45 Late (25) + Sporadic N/I PULSAR FLEXeas 24
13 F 38 Late (10) + AR N/I PULSAR FLEXeas 24
14 F 60 Late (40) + AD N/I Combi 40+ standard 31.5
15 M 68 Late (50) + Sporadic N/I PULSAR FLEXsoft 31.5
16 M 12 Early (3)* + AR CDH23 PULSAR FLEXsoft 31.5
17 M 12 Early (1 year
8 months)*
+A R CDH23 PULSAR FLEXsoft 31.5
18 M 1 Early (0)
† NA Sporadic CDH23 PULSAR FLEXsoft 31.5
N/I, not identiﬁed within four genes.
*Most probably congenital.
†Newborn hearing screening.
378 S. Usami et al.(average for all frequencies from 125 to 8000 Hz)
1 year after cochlear implantation. Their word rec-
ognition scores in quiet improved from 64% to 76%
(no. 16) and from 60% to 76% (no. 17) at 1 year
postoperatively.
Case no. 18 (Figure 3)
This case was a 1-year-old boy with the CDH23
mutations. Auditory steady-state response (ASSR)
evaluated at the age of 4 and 7 months showed
some residual hearing at 500 Hz in the right ear
(Figure 3D). He ﬁrst received a left cochlear implant
(MEDEL PULSAR CI100/standard electrode) at the
age of 9 months. The parents wanted him to use a
cochlear implant on the right side as well, and we
decided to use a more atraumatic electrode (MEDEL
PULSAR CI100/FLEXsoft electrode) because of the
possible residual hearing in the low frequencies
(Figure 3A, B, C). The second cochlear implant sur-
gery was performed at the age of 12 months. Residual
hearing measured by conditioned orientation reﬂex
(COR) audiometry [7] was well preserved 1 year after
cochlear implantation (Figure 3D). This patient had
compound heterozygous mutations (p.[D1216A;
V1807M]/p.Q1716P) and the parents were found to
be carriers for these mutations (Figure 3E). Although
the patient was too young to undergo ophthalmologic
examination, he did not have any problems in vision or
any vestibular problems, and there is no indicative
evidence for Usher syndrome at this time.
In this very young case, auditory behavioral develop-
ment was assessed by using the LittlEARS
  Auditory
Questionnaire, which has been designed for children
under the age of 2 years [8,9]. The development
curve showed a rapid increase in auditory behavior
and reached the score seen in normally developed
children (c 3F).
Case no. 9 (Figure 4)
This case was a 52-year-old male with the 1555A>G
mitochondrial mutation. He noticed hearing loss
around age 38 and used hearing aids, but his hearing
losswasslowlyprogressiveasevaluatedbyserialaudio-
grams.Duetoresidualhearinginthelowerfrequencies,
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Figure 1. Case no. 16. (A) Endoscopic view of round window insertion, (B) montage CT image, (C) imaging with putative location of
electrode and the referential tonotoic map, (D) preoperative and postoperative audiograms. The image of human cochlea neural tissues stained
by osmium tetroxide used in Figures 1,2,3,4 was kindly provided by Dr C.G. Wright, USWT, Dallas, USA (red, mm from round window;
black, corresponding frequency). (E) Pedigree and the mutations found in the CDH23 gene.
EAS for CDH23 and mitochondrial 1555A>G mutation patients 379an atraumatic electrode (MEDEL PULSAR CI100/
FLEXeas electrode) was chosen (Figure 4A, B, C).
Residual hearing was well preserved at 2 months post-
operatively (Figure 4D). His parents had hearing loss,
and the pedigree was consistent with mitochondrial
inheritance (as well as autosomal dominant inheri-
tance) (Figure 4E). Genetic screening detected the
1555 mitochondrial mutation in the patient and his
mother. He had no history of exposure to amino-
glycoside antibiotics. No vestibular symptoms were
noted, and no abnormal ﬁndings were seen in vesti-
bular testing including caloric response and vestibular
evoked myogenic potential (VEMP). His hearing
threshold improved to 30 dB (average for all frequen-
cies from 125 to 8000 Hz) 2 months after cochlear
implantation. Due to an insufﬁcient follow-up
period, his speech recognition score has not yet been
evaluated.
Discussion
Aspredictedfrom ourpreviousstudy [1]usingpatients
who fulﬁlled the criteria for EAS, the CDH23
mutations and the 1555A>G mitochondrial mutation
were in fact found among our series of EAS patients.
Our previous study indicated that the CDH23
mutations were frequently found in patients with
recessive inheritance and the presence of residual
hearing is one particular phenotypic feature of the
patients with CDH23 mutations [5], and actually all of
the early-onset patients had the mutations in this
gene.
The CDH23 gene encodes cadherin 23, a protein
thought to be a molecule that forms the lateral links
between the stereocilia of hair cells [10]. One remark-
ableresultinthisstudyisthatfunctionofthelaterallinks
remained stable even after deep insertion of the elec-
trode of the cochlear implant. Such functional preser-
vation enabled hearing preservation even in the
presence of an electrode covering the corresponding
frequency region.
As suggested by genotype–phenotype correlation
study, USH1D, which has a more severe phenotype
including severe to profound hearing loss, vestibular
dysfunction, and retinitis pigmentosa, is usually asso-
ciated with nonsense, splicing-site, and frameshift
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Figure 2. Case no. 17. (A) Endoscopic view of round window insertion, (B) montage CT image, (C) imaging with putative location of
electrode and the referential tonotoic map, (D) preoperative and postoperative audiograms. (E) Pedigree and the mutations found in the
CDH23 gene.
380 S. Usami et al.mutations. In contrast, DFNB12, which has a milder
phenotype, is associated with missense mutations
[11,12]. The mutations found in the present three
cases (we previously reported case nos 16 and 17 as
family no. 3 [5]) are consistent with the general
genotype–phenotype correlation rule.
In Usher type I patients, known to have the same
etiology, improvement in sound detection as well as
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Figure 3. Case no. 18. (A) Endoscopic view of round window insertion, (B) montage CT image, (C) imaging with putative location of
electrode and the referential tonotoic map, (D) preoperative ASSR ﬁndings (blue, left; red, right) and postoperative COR audiogram ﬁnding.
(E) Pedigree and the mutations found in the CDH23 gene. (F) Auditory behavioral development assessed by LittlEARS
  Auditory
Questionnaire. The development curve shows rapid improvement in auditory behavior reaching the curve of normally developed children.
EAS for CDH23 and mitochondrial 1555A>G mutation patients 381speech perception was seen in all patients, especially
younger ones [13]. The present study clearly indicates
that patients with the CDH23 mutations are good
candidates for EAS. The previous report together
with the present cases indicates that progressiveness
of hearing loss is a characteristic feature of the patients
with this mutation [5,12]. Therefore, deep insertion
with longer electrodes is recommended to prevent
future deterioration. Successful hearing preservation
and prediction of future hearing level by genetic
diagnosis may facilitate decision making for early
intervention.
It is interesting that GJB2, the most prevalent
causative gene among the prelingual patients, was
not found in the present series of patients. This is
probably due to their more or less ﬂat audiograms [1]
and therefore they may be good candidates for con-
ventional cochlear implantation.
In very young children, pure tone audiograms are
not available. Acoustic brainstem response (ABR) is
usually used to evaluate their hearing, but it is difﬁcult
to measure residual hearing in the low frequencies.
Recently, acoustic steady-state response (ASSR) has
been clinically available to measure hearing levels of
500 Hz or 250 Hz, but sometimes the low frequency
part is not reliable or convincing [14]. In addition to
such hearing testing, genetic testing is useful to predict
the residual hearing at low frequencies. Especially for
cases with CDH23 mutations, predicted audiograms
can be obtained for the very young patients. Based on
this concept, together with consideration of their
expected long life (which includes a risk of progres-
sion), we chose a longer atraumatic electrode
(MEDEL PULSAR CI100/FLEXsoft electrode) for
three patients with CDH23 mutations.
It is known that patients with the 1555A>G mito-
chondrial mutation are susceptible to aminoglycoside
antibiotics [15]. The 1555A>G mutation is one of the
most important mutations among the hearing loss
population in Japan, and approximately 3% of
patients with sensorineural hearing loss possess this
mutation [16]. Their hearing loss is known to be
slowly progressive [6,17]. This mutation is an impor-
tant cause in the post-lingual cochlear implant
patients, found in 10% of them [16]. It has been
reported that a patient with cochlear implantation
showed excellent auditory performance [18], indicat-
ing that cochlear implantation is a valuable choice of
therapy for patients with profound hearing loss caused
by this mutation. This mutation was also found in
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Figure 4. Case no. 9. (A) Endoscopic view of round window insertion, (B) postoperative X-ray ﬁnding, (C) imaging with putative location of
electrode and the referential tonotoic map, (D) preoperative and postoperative audiograms. (E) Pedigree and the subjects with the
mitochondrial 1555 mutations.
382 S. Usami et al.patients without any aminoglycoside exposure and
their hearing loss was usually milder than those
with aminoglycoside exposure [19]. Environmental
causative factors other than aminoglycoside antibio-
tics – such as noise or mechanical stress – have been
speculated, although not conﬁrmed. The present
study provided an important clinical experience that
EAS could be safely performed even if the patients
have this mutation and therefore possible association
of susceptibility for any mechanical stress.
For outcome of EAS, together with successful
hearing preservation, all four patients obtained
25–35 dB in average hearing threshold after implan-
tation. Since EAS was implanted as a second cochlear
implant for three cases with CDH23 mutations, it is
difﬁcult to evaluate the independent beneﬁt of EAS.
However, improvement of word recognition scores
after EAS was observed in case nos 16 and 17,
indicating that additive beneﬁt was clearly obtained
even after a rather long period following the ﬁrst
implants (at 7 years and 6 years, respectively). For
case no. 18, although it is also difﬁcult to evaluate
the independent beneﬁt of EAS because of the very
young age, the auditory behavioral development as
assessed by the LittlEARS
  Auditory Questionnaire
was signiﬁcantly improved after two consecutive
implantations. Since the CDH23 mutation will be
potentially found in rather young candidates, this
genetic marker could be available for the existence
of residual hearing. For those patients, it is strongly
suggested that the surgeon keep in mind the option of
performing atraumatic surgery.
In the present series, there are many families with
autosomal dominant hearing loss (6 of 18), suggesting
that many other genes responsible for dominant
hearing loss may be involved. It is also important to
note that all of the patients showed progressive hearing
loss. We are currently searching for the responsible
genes for the patients with high frequency hearing loss.
In conclusion, the CDH23 mutations and the
1555A>G mitochondrial mutation were identiﬁed
among our series of EAS patients, conﬁrming that
these genes were important in high frequency hearing
loss. Successful hearing preservation in these patients
as well as good outcomes of EAS indicated that those
withthesemutationsaregood candidatesforEAS.The
present study indicates that genetic testing provides
useful information regarding residual hearing and
consequent therapeutic options.
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